Thursday, Par Pharmaceutical Companies Inc. (PRX) received final approval from the U.S. Food and Drug Administration or FDA for its Abbreviated New Drug Application for nateglinide tablets. Nateglinide is a generic version of Novartis' Starlix. Par will begin shipping the 60mg and 120mg strengths of nateglinide to the trade immediately. Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes mellitus.
Par Pharmaceutical Companies Inc., through its subsidiary, Par Pharmaceutical Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States.
For comments and feedback: editorial@rttnews.com